Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 953
Filter
1.
Chinese Medical Journal ; (24): 2203-2209, 2023.
Article in English | WPRIM | ID: wpr-1007639

ABSTRACT

BACKGROUND@#Limited data are available on the changes in the quality of care for ST elevation myocardial infarction (STEMI) during China's health system reform from 2009 to 2020. This study aimed to assess the changes in care processes and outcome for STEMI patients in Henan province of central China between 2011 and 2018.@*METHODS@#We compared the data from the Henan STEMI survey conducted in 2011-2012 ( n = 1548, a cross-sectional study) and the Henan STEMI registry in 2016-2018 ( n = 4748, a multicenter, prospective observational study). Changes in care processes and in-hospital mortality were determined. Process of care measures included reperfusion therapies, aspirin, P2Y12 antagonists, β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins. Therapy use was analyzed among patients who were considered ideal candidates for treatment.@*RESULTS@#STEMI patients in 2016-2018 were younger (median age: 63.1 vs . 63.8 years) with a lower proportion of women (24.4% [1156/4748] vs . 28.2% [437/1548]) than in 2011-2012. The composite use rate for guideline-recommended treatments increased significantly from 2011 to 2018 (60.9% [5424/8901] vs . 82.7% [22,439/27,129], P <0.001). The proportion of patients treated by reperfusion within 12 h increased from 44.1% (546/1237) to 78.4% (2698/3440) ( P <0.001) with a prolonged median onset-to-first medical contact time (from 144 min to 210 min, P <0.001). The use of antiplatelet agents, statins, and β-blockers increased significantly. The risk of in-hospital mortality significantly decreased over time (6.1% [95/1548] vs . 4.2% [198/4748], odds ratio [OR]: 0.67, 95% confidence interval [CI]: 0.50-0.88, P = 0.005) after adjustment.@*CONCLUSIONS@#Gradual implementation of the guideline-recommended treatments in STEMI patients from 2011 to 2018 has been associated with decreased in-hospital mortality. However, gaps persist between clinical practice and guideline recommendation. Public awareness, reperfusion strategies, and construction of chest pain centers need to be further underscored in central China.


Subject(s)
Humans , Female , Middle Aged , ST Elevation Myocardial Infarction/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Cross-Sectional Studies , Aspirin/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Adrenergic beta-Antagonists/therapeutic use , Hospital Mortality , Registries , Treatment Outcome , Percutaneous Coronary Intervention
2.
Braz. J. Anesth. (Impr.) ; 73(4): 426-433, 2023. tab, graf
Article in English | LILACS | ID: biblio-1447630

ABSTRACT

Abstract Background Few trials have examined the efficacy of esmolol to attenuate hemodynamic and respiratory responses during extubation. However, the most appropriate dose of esmolol and an optimal protocol for administering this beta-blocker are uncertain. Methods Ninety patients ASA physical status I, II, and III (aged 18-60 years) scheduled to procedures with general anesthesia and tracheal extubation were selected. Patients were randomized into esmolol and placebo group to evaluate the efficacy and safety of a single bolus dose of esmolol (2 mg.kg-1) on cardiorespiratory responses during the peri-extubation period. The primary outcome was the rate of tachycardia during extubation. Results The rate of tachycardia was significantly lower in esmolol-treated patients compared to placebo-treated patients (2.2% vs. 48.9%, relative risk (RR): 0.04, 95% confidence interval (95% CI) = 0.01 to 0.32, p= 0.002). The rate of hypertension was also significantly lower in the esmolol group (4.4% vs. 31.1%, RR: 0.14, 95% CI 0.03 to 0.6, p= 0.004). Esmolol-treated patients were associated with higher extubation quality compared to patients who received placebo (p< 0.001), with an approximately two-fold increase in the rate of patients without cough (91.1%) in the esmolol group compared to the placebo group (46.7%). The rate of bucking was approximately 5-fold lower in the esmolol group (8.9% vs. 44.5%, respectively, RR: 0.20 (95% CI, 0.1 to 0.5, p= 0.002, with an NNT of 2.8). Conclusion A single bolus dose of esmolol is an effective and safe therapeutic strategy to attenuate cardiorespiratory responses during the peri-extubation period.


Subject(s)
Humans , Propanolamines/therapeutic use , Propanolamines/pharmacology , Hypertension/ethnology , Hypertension/drug therapy , Tachycardia/ethnology , Tachycardia/prevention & control , Tachycardia/drug therapy , Adrenergic beta-Antagonists/therapeutic use , Adrenergic beta-Antagonists/pharmacology , Airway Extubation/adverse effects , Heart Rate , Anesthesia, General/adverse effects
3.
Arch. pediatr. Urug ; 94(1): e301, 2023. ilus
Article in Spanish | LILACS, UY-BNMED, BNUY | ID: biblio-1420111

ABSTRACT

Se presenta un neonato con hemangioma cérvico facial y posterior diagnóstico de hemangioma subglótico. Los hemangiomas en el período neonatal y los primeros meses de vida requieren una atención cuidadosa. Debido a su patrón de crecimiento y la futura aparición de nuevas lesiones, son considerados imprevisibles en esta etapa. Se encontró una fuerte asociación entre los hemangiomas difusos de localización cérvico facial y los hemangiomas sintomáticos de la vía aérea alta. El riesgo está relacionado con el grado de extensión de la afectación cutánea en un área que incluye la piel de la región mandibular, el mentón, el labio inferior y la parte anterior del cuello. Los hemangiomas infantiles requieren tratamiento cuando presentan riesgo vital y alteraciones funcionales, como compromiso de la vía aérea.


This is the case of a newborn with cervical hemangioma and a subsequent diagnosis of subglottic hemangioma. Hemangiomas in neonates and infants require careful attention. Due to their growth pattern and the potential appearance of new lesions, they are considered unpredictable at this stage. A strong link was found between diffuse cervical-facial and symptomatic upper airway hemangiomas. The risk is related to the extent of skin involvement in a given area, which might include the jaw, chin, lower lip, and front of the neck skin. Infant hemangiomas require treatment when they present life-threatening and functional alterations, such as airway compromise.


Relatamos o caso de um recém-nascido com hemangioma cervical com diagnóstico posterior de hemangioma subglótico. Hemangiomas em recém-nascidos e lactentes requerem atenção cuidadosa. Devido ao seu padrão de crescimento e ao potencial aparecimento de novas lesões, são considerados imprevisíveis nessa fase. Uma forte associação foi encontrada entre hemangiomas cervicofaciais difusos e hemangiomas sintomáticos das vias aéreas superiores. O risco está relacionado à extensão do envolvimento da pele da mandíbula, o queixo, o lábio inferior e a pele da frente do pescoço. Os hemangiomas infantis necessitam de tratamento quando apresentam alterações funcionais ou risco de vida, como comprometimento das vias aéreas.


Subject(s)
Humans , Female , Facial Neoplasms/diagnosis , Laryngeal Neoplasms/diagnosis , Hemangioma/diagnosis , Propranolol/therapeutic use , Infant, Premature , Facial Neoplasms/drug therapy , Laryngeal Neoplasms/drug therapy , Adrenergic beta-Antagonists/therapeutic use , Hemangioma/complications
4.
Rev. ADM ; 79(4): 213-217, jul.-ago. 2022.
Article in Spanish | LILACS | ID: biblio-1395859

ABSTRACT

La cardiopatía isquémica es un padecimiento que se caracteriza por la falta de oxígeno del músculo cardiaco y es la principal causa de infarto de miocardio. Existen múltiples factores que predisponen al desarrollo de ésta como la obesidad, la hiperlipidemia, el sedenta- rismo, tabaquismo, diabetes e hipertensión. Dadas las características que configuran la fisiopatología de la cardiopatía isquémica, existen diversas consideraciones que deben ser tomadas en cuenta toda vez que el estomatólogo brinde atención a un paciente con este padecimiento. El objetivo del presente artículo es conocer todo lo relacionado con la fisiopatología de la cardiopatía isquémica, sus manifestaciones clínicas, su tratamiento médico y lo más importante, las consideraciones que deben tomarse en el consultorio dental cuando se atienda a un paciente que padezca esta condición (AU)


Ischemic heart disease is a condition characterized by a lack of oxygen in the heart muscle and is the main cause of myocardial infarction. There are multiple factors that predispose to the development of this, such as obesity, hiyperlipidemia, sedentary lifestyle, smoking, diabetes and hypertension. Given the characteristics that make up the pathophysiology of ischemic heart disease, there are various considerations that must be taken into account whenever the stomatologist provides care to a patient with this condition. The objective of this article is to know everything related to the pathophysiology of ischemic heart disease, its clinical manifestation, its medical treatment and most importantly, the considerations that must be taken in the dental office when caring for a patient with this condition (AU)


Subject(s)
Humans , Myocardial Ischemia/etiology , Myocardial Ischemia/drug therapy , Dental Care for Chronically Ill/methods , Myocardial Infarction/complications , Cardiovascular Diseases/prevention & control , Risk Factors , Myocardial Ischemia/epidemiology , Adrenergic beta-Antagonists/therapeutic use , Sedentary Behavior , Fibrinolytic Agents/therapeutic use , Nitrates/therapeutic use
5.
Chinese Journal of Cardiology ; (12): 480-485, 2022.
Article in Chinese | WPRIM | ID: wpr-935173

ABSTRACT

Objective: To evaluate the consistency on the determination of target heart rate by simple calculation method based on resting heart rate and by anaerobic threshold method in cardiopulmonary exercise test (CPET) for patients with coronary artery disease after percutaneous coronary intervention (PCI). Methods: This study was a diagnostic test. Patients with coronary artery disease who underwent the first PCI in the Department of Cardiology of Peking University People's Hospital from October 2011 to April 2021 were enrolled. Patients were further divided into subgroups according to gender, age (<60 years group and ≥60 years group), with or without myocardial infarction history (myocardial infarction group and angina pectoris group) and whether β blockers were applied. The general clinical data of patients, resting heart rate (RHR) and anaerobic threshold heart rate in CPET were collected through the electronic medical record system. The simple target rate (RHR plus 20 or 30 bpm) and the target rate calculated by anaerobic threshold (anaerobic threshold heart rate minus 10 bpm) were both calculated in each patient. Consistency test of target heart rate derived by above the two methods was shown by intra-class correlation (ICC) and Bland-Altman plots. Results: A total of 439 patients were included, age was (56.2±8.8) years, body mass index was (25.77±2.34) kg/m2, there were 382 males (87.0%). The target heart rate determined by anaerobic threshold method was (90.0±11.8)bpm, and the simple target heart rate determined by RHR plus 20 bpm was (91.0±8.4)bpm. There was no significant difference on the target heart rate derived from the two calculation methods (P=0.091). The simple target heart rate determined by RHR plus 30 bpm was (101.0±8.4)bpm, which was significant higher than that determined by anaerobic threshold method (P<0.001). In the following analysis, RHR plus 20 bpm was defined as the simple target heart rate. The ICC value of target heart rate determined by anaerobic threshold and resting rate plus 20 bpm was 0.529(95%CI 0.458-0.593, P<0.001). Bland-Altman plots analysis showed that the ratio of the simple target heart rate and the target heart rate determined by anaerobic threshold method was 1.03±0.11 and the 95% limits of agreement (LOA) were 0.812-1.245. In the subgroup of patients aged<60 years (n=247), the ICC value was 0.492, the ratio by Bland-Altman plots analysis was 1.02±0.11 and LOA was 0.814-1.234; in the subgroup of patients aged ≥60 years (n=192), the ICC value was 0.566, the ratio by Bland-Altman plots analysis was 1.03±0.11 and LOA was 0.810-1.260. In male subgroup(n=382), the ICC value was 0.540, the ratio by Bland-Altman plots analysis was 1.03±0.11 and LOA was 0.813-1.246; in female subgroup(n=57), the ICC value was 0.445, the ratio by Bland-Altman plots analysis was 1.03±0.11 and LOA was 0.810-1.240.In myocardial infarction subgroup (n=186), the ICC value was 0.568, the ratio by Bland-Altman plots analysis was 1.02±0.11 and LOA was 0.810-1.227; in angina pectoris subgroup (n=253), the ICC value was 0.495, the ratio by Bland-Altman plots analysis was 1.04±0.11 and LOA was 0.813-1.260. In the subgroup of patients with β blockers (n=353), the ICC value was 0.520, the ratio by Bland-Altman plots analysis was 1.03±0.11 and LOA was 0.810-1.252; in the subgroup of patients without β blockers (n=86), the ICC value was 0.570, the ratio by Bland-Altman plots analysis was 1.02±0.10 and LOA was 0.821-1.219. Conclusions: The simple target heart rate determined by RHR plus 20 bpm is consistent with the target heart rate determined by anaerobic threshold in patients with coronary artery disease after PCI. But the simple target heart rate determined by RHR plus 20 bpm can't replace the target heart rate determined by anaerobic threshold in this patient cohort.


Subject(s)
Female , Humans , Male , Adrenergic beta-Antagonists , Anaerobic Threshold , Angina Pectoris , Coronary Artery Disease , Heart Rate/physiology , Myocardial Infarction , Percutaneous Coronary Intervention
6.
Chinese Journal of Cardiology ; (12): 886-893, 2021.
Article in Chinese | WPRIM | ID: wpr-941372

ABSTRACT

Objective: To analyze the status of early use of oral β-blocker and its relationship with in-hospital outcomes in eligible patients with acute coronary syndrome (ACS). Methods: The study was based on the Improving Care for Cardiovascular Disease in China (CCC)-ACS project. The data of ACS patients that collected during 2014 to 2019 from 230 collaborating hospitals across China were analyzed. Propensity score matching method and Cox multivariate regression analysis were used to analyze the association between early use of oral β-blocker and in-hospital outcomes within 15 days. Results: A total of 38 663 eligible ACS patients were included in this study. The mean age was (57.0±9.0), and 78.8% of the ACS patients (30 470/38 663) were male. The proportion of early use of oral β-blockers was 64.9% (25 112/38 663), but varied substantially, in the 230 hospitals with a range from 0 to 100%. Compared with the patients no early use of oral β-blocker, the patients receiving early oral β-blocker had significantly lower incidence of major cardiovascular adverse events (MACEs) (3.4% (395/11 536) vs. 2.9%(339/11 536), P=0.036)and less occurrences of heart failure (2.7% (316/11 536) vs. 2.1% (248/11 536), P=0.004). Multivariate Cox regression analyses showed the patients receiving early oral β-blocker had 15.5%, 23.1%, and 35.3% lower risks of MACEs, heart failure and cardiogenic shock respectively than the patients no early oral β-blocker. Conclusions: Compared with the patients no early oral β-blocker, the patients receiving early oral β-blocker had lower risks of MACEs events, heart failure and cardiogenic shock. However, the early use of oral β-blocker in ACS patients was generally insufficient with huge differences among different hospitals in China.


Subject(s)
Humans , Male , Acute Coronary Syndrome/drug therapy , Adrenergic beta-Antagonists/therapeutic use , Heart Failure , Hospitals , Shock, Cardiogenic
7.
Acta pediátr. hondu ; 12(2): 1279-1282, oct. 2021-marz. 2022.
Article in Spanish | LILACS, BIMENA | ID: biblio-1435809

ABSTRACT

La intoxicación por betabloqueadores es una situación clínica de poca frecuencia, estrechamente relacionada con trastornos depresivos mayores, con una prevalencia mayor en mujeres. Los episodios de gravedad relacio- nados a toxicidad por betabloqueadores son clasificados como episodios de moderados a severos. En el caso del carvedilol con un umbral tóxico de 50mg. Caso Clínico: Paciente de 16 años con historia de ingesta de carvedilol en niveles tóxicos y único antecedente depresión ma- yor. Discusión: Los betabloqueadores antagonizan los receptores betaadrenérgicos, la sintomatología relacio- nada con bradicardia e hipotensión es frecuente y puede generar afección a nivel del sistema nervioso central. El tratamiento de emergencia sí se capta al paciente en la primera hora consiste en realizar un lavado gástrico y aplicar carbón activado. Se propone el uso de crista- loides y el uso de epinefrina o norepinefrina como ma- nejo de primera línea, en caso de bradicardias sosteni- das debe considerarse el uso de atropina. Los pacientes asintomáticos deben ser vigilados durante seis horas...(AU)


Subject(s)
Humans , Male , Adolescent , Adrenergic beta-Antagonists/toxicity , Carvedilol/toxicity , Atropine/therapeutic use , Charcoal/therapeutic use
8.
São José dos Campos; s.n; 2021. 107 p. ilus, graf, tab.
Thesis in Portuguese | LILACS, BBO | ID: biblio-1362411

ABSTRACT

O objetivo deste estudo foi analisar os efeitos do estresse crônico sobre a periodontite apical (PA) induzida em ratos, e avaliar os efeitos do uso da Fluoxetina (antidepressivo da classe dos inibidores da recaptação de serotonina) e do Propranolol (bloqueador beta-adrenérgico), associados ou não, na modulação inflamatória e na reabsorção óssea periapical de ratos estressados. Foram utilizados 40 ratos divididos em cinco grupos: Grupo controle não-estressado (NS); Grupo controle estressado com administração de solução fisiológica (SS); Grupo estressado com administração de Fluoxetina (SF); Grupo estressado com administração de Propranolol (SP); Grupo estressado com administração de Fluoxetina e Propranolol (SFP). Os animais dos grupos estressados foram submetidos ao protocolo de estresse crônico imprevisível durante 6 semanas e as respectivas medicações foram administradas diariamente, via gavagem, ao longo de todo o período experimental. A PA foi induzida em todos os grupos após 21 dias do início do protocolo de estresse e ao final da 6ª semana, os animais foram eutanasiados e as hemimandíbulas e hemimaxilas removidas. Posteriormente foram realizadas as seguintes análises: a) da massa corporal; b) dos níveis séricos de corticosterona por radioimunoensaio; c) dos níveis séricos hormonais e inflamatórios por ensaio Multiplex; e) histomorfométrica por coloração com hematoxilina e eosina; f) da estrutura óssea periapical através de microtomografia computadorizada (micro-CT); g) da expressão gênica de biomarcadores relacionados à atividade osteoclástica, citocinas inflamatórias e metaloproteinases na região periapical por RT-PCR. Ao final do experimento os animais estressados apresentaram menor ganho de massa corporal, níveis séricos de ACTH significativamente mais altos, atividade inflamatória mais intensa e maiores volumes de lesão periapical quando comparados aos animais do grupo controle NS. Os grupos tratados SF, SP e SFP apresentaram menores volumes de lesão periapical quando comparados ao grupo controle SS, e o grupo SP apresentou menor intensidade do infiltrado inflamatório. O teste de RT-PCR mostrou maior expressão de RANKL e TRAP no grupo controle SS, bem como maior expressão de IL-6, IL-10 e IL-17 e MMP-8 quando comparado ao grupo controle NS. Na comparação em relação ao grupo controle SS, o grupo SF apresentou maior expressão de OPG, e menor expressão de IL-6 e IL-17; o grupo SP apresentou maior expressão de OPG e menor expressão de IL-6, IL-10, IL-17, MMP-8 e MMP-13, e o grupo SFP apresentou menor expressão de RANKL, TRAP, IL-6, IL-10, IL-17, MMP-8 e MMP-13. Foi concluído que o estresse crônico influenciou negativamente a patogênese da PA e ambos os medicamentos avaliados, bem como sua associação, tiveram efeitos positivos na prevenção da perda óssea e modulação inflamatória.


The aim of this study was to analyze the effects of chronic stress on induced apical periodontitis (AP) in rats, and to evaluate the effects of the use of fluoxetine (antidepressant known as selective serotonin reuptake inhibitor), and of Propranolol (beta-adrenergic blocker), associated or not, in inflammatory modulation and periapical bone resorption in stressed rats. Forty rats were divided into five groups: Unstressed control group (NS); Stressed control group with saline solution administration (SS); Stressed group with administration of Fluoxetine (SF); Stressed group with administration of Propranolol (SP); Stressed group with administration of Fluoxetine and Propranolol (SFP). The animals in the stressed groups were submitted to the unpredictable chronic stress paradigm for 6 weeks and the respective medications were administered daily, via gavage, throughout the entire experimental period. AP was induced in all groups, 21 days after the beginning of the stress paradigm, and at the end of the 6th week, the animals were euthanized and the hemi-mandibles removed for the following analyses: a) body weight b) serum corticosterone levels by radioimmunoassay; c) hormone and inflammatory serum levels by Multiplex assay; e) histomorphometric staining with hematoxylin and eosin; f) the periapical bone structure through computerized microtomography; g) gene expression related to osteoclastic activity, inflammatory cytokines and metalloproteinases in the periapical region by RT-PCR. At the end of the experiment, the stressed animals showed lower body weight gain, significantly higher levels of ACTH, more intense inflammatory infiltrate and higher volumes of periapical lesion when compared to animals in the NS control group. The treated groups SF, SP and SFP had smaller volumes of periapical lesion when compared to the SS control group and the SP group had lower intensity of inflammatory infiltrate. The RT-PCR test showed higher expression of RANKL and TRAP in the stressed control group, as well as higher expression of IL-6, IL-10, IL-17 and MMP-8 when compared to the NS control group. In comparison with the SS control group, the SF group showed higher expression of OPG, and lower expression of IL-6 and IL-17; the SP group showed higher expression of OPG and lower expression of IL-6, IL-10, IL-17, MMP-8 and MMP-13 and the SFP group showed lower expression of RANKL, TRAP, IL-6, IL-10, IL-17, MMP-8 and MMP-13. It was concluded that chronic stress negatively influenced the pathogenesis of apical periodontitis and both medications evaluated, as well as its association, had positive effects in preventing bone loss and inflammatory modulation.


Subject(s)
Animals , Rats , Periapical Periodontitis , Stress, Physiological , Selective Serotonin Reuptake Inhibitors , Adrenergic beta-Antagonists , Propranolol , Bone Resorption , Fluoxetine , Analysis of Variance , Statistics, Nonparametric , Euthanasia, Animal
9.
Arq. bras. cardiol ; 115(6): 1063-1069, dez. 2020. tab, graf
Article in Portuguese | LILACS | ID: biblio-1152946

ABSTRACT

Resumo Fundamento Estudos revelam que pacientes com insuficiência cardíaca (IC) e frequência cardíaca (FC) <70 batimentos por minuto (bpm) evoluem melhor e têm menor morbimortalidade em comparação com FC >70. Entretanto, muitos pacientes com IC mantêm FC elevada. Objetivo Avaliar se os pacientes acompanhados em ambulatório de cardiologia têm sua FC controlada e como estava a prescrição dos medicamentos que reduzem a mortalidade na IC. Métodos Foram analisados de forma consecutiva pacientes que passaram em consulta e que já acompanhavam em ambulatório de cardiologia, idade > 18 anos e com diagnóstico de IC e fração de ejeção do ventrículo esquerdo (FEVE) <45%. Os pacientes em ritmo sinusal foram divididos em dois grupos: FC ≤70 bpm (G1) e FC >70 bpm (G2). Na análise estatística, foram utilizados os testes t de Student, Qui-quadrado. Foi considerado significante p <0,05. Utilizamos o programa Statistical Package for the Social Sciences (SPSS) para análise. Resultados Foram avaliados 212 pacientes de forma consecutiva. Destes, 41 (19,3%) apresentavam fibrilação atrial ou eram portadores de marca-passo e foram excluídos desta análise; assim, 171 pacientes foram analisados. Os pacientes em ritmo sinusal tinham idade média de 63,80 anos (±11,77), sendo 59,6% homens e FEVE média de 36,64% (±7,79). Com relação à etiologia, a isquêmica estava presente em 102 pacientes (59,65%), enquanto a cardiopatia chagásica em 17 pacientes (9,9%); 131 pacientes eram hipertensos (76,6%), enquanto 63 pacientes (36,84%) eram diabéticos. Quanto à FC, 101 pacientes apresentaram FC ≤70 bpm (59,06%) G1 e 70 pacientes (40,93%) FC >70 bpm (G2). A FC média no G1 foi de 61,53 bpm (±5,26) e no G2, 81,76 bpm (±9,52), p <0,001. A quase totalidade dos pacientes (98,8%) estava sendo tratada com carvedilol prescrito na dose média de 42,14 mg/dia (±18,55) no G1 versus 42,48 mg/dia (±21,14) no G2, p=0,911. A digoxina foi utilizada em 5,9% dos pacientes no G1 versus 8,5% no G2, p=0,510. A dose média de digoxina no G1 foi de 0,19 mg/dia (±0,06) e no G2 foi de 0,19 mg/dia (±0,06), p=0,999. A maioria dos pacientes (87,72%) utilizou o inibidor da enzima de conversão da angiotensina (IECA) ou bloqueador do receptor da angiotensina (BRA), e 56,72% utilizaram espironolactona. A dose média de enalapril foi de 28,86 mg/dia (±12,68) e de BRA foi de 87,80 mg/dia (±29,80). A maioria dos pacientes utilizou IECA ou BRA e com doses adequadas. Conclusão O estudo revelou que 40,93% dos pacientes estavam com FC acima de 70 bpm, apesar de o betabloqueador ter sido prescrito para praticamente todos os pacientes e em doses elevadas. Outras medidas precisam ser adotadas para manter a FC mais controlada nesse grupo de frequência mais elevada. (Arq Bras Cardiol. 2020; 115(6):1063-1069)


Abstract Background Studies have shown that heart failure (HF) patients with heart rate (HR) < 70 bpm have had a better clinical outcome and lower morbidity and mortality compared with those with HR > 70 bpm. However, many HF patients maintain an elevated HR. Objective To evaluate HR and the prescription of medications known to reduce mortality in HF patients attending an outpatient cardiology clinic. Methods We consecutively evaluated patients seen in an outpatient cardiology clinic, aged older than 18 years, with diagnosis of HF and left ventricular ejection fraction (LVEF) < 45%. Patients with sinus rhythm were divided into two groups - HR ≤ 70 bpm (G1) and HR > 70 bpm (G2). The Student's t-test and the chi-square test were used in the statistical analysis, and a p-value < 0.05 was considered statistically significant. The SPSS software was used for the analyses. Results A total of 212 consecutive patients were studied; 41 (19.3%) had atrial fibrillation or had a pacemaker implanted and were excluded from the analysis, yielding 171 patients. Mean age of patients was 63.80 ± 11.77 years, 59.6% were men, and mean LVEF 36.64±7.79%. The most prevalent HF etiology was ischemic (n=102; 59.6%), followed by Chagasic (n=17; 9.9%). One-hundred thirty-one patients (76.6%) were hypertensive and 63 (36.8%) diabetic. Regarding HR, 101 patients had a HR ≤70 bpm (59.1%) and 70 patients (40.93%) had a HR >70 bpm (G2). Mean HR of G1 and G2 was 61.5±5.3 bpm and 81.8±9.5 bpm, respectively (p<0.001). Almost all patients (98.8%) were receiving carvedilol, prescribed at a mean dose of 42.1±18.5 mg/day in G1 and 42.5±21.1mg/day in G2 (p=0.911). Digoxin was used in 5.9% of patients of G1 and 8.5% of G2 (p=0.510). Mean dose of digoxin in G1 and G2 was 0.19±0.1 mg/day and 0.19±0.06 mg/day, respectively (p=0,999). Most patients (87.7%) used angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), and 56.7% used spironolactone. Mean dose of enalapril was 28.9±12.7 mg/day and mean dose of ARB was 87.8±29.8 mg/day. The doses of ACEI and ARB were adequate in most of patients. Conclusion The study revealed that HR of 40.9% of patients with HF was above 70 bpm, despite treatment with high doses of beta blockers. Further measures should be applied for HR control in HF patients who maintain an elevated rate despite adequate treatment with beta blocker. (Arq Bras Cardiol. 2020; 115(6):1063-1069)


Subject(s)
Humans , Male , Female , Adolescent , Aged , Angiotensin Receptor Antagonists , Heart Failure/drug therapy , Stroke Volume , Angiotensin-Converting Enzyme Inhibitors , Ventricular Function, Left , Treatment Outcome , Adrenergic beta-Antagonists/therapeutic use , Heart Rate , Middle Aged
10.
An. bras. dermatol ; 95(2): 207-209, Mar.-Apr. 2020. graf
Article in English | LILACS, ColecionaSUS | ID: biblio-1130852

ABSTRACT

Abstract Infantile hemangioma is the most common pediatric vascular tumor, with the following risk factors: low birth weight, prematurity, white skin, female gender, multiparity and advanced maternal age. The use of oral and topical beta-blockers, although recent, has emerged as the first line of treatment, with superior safety and efficacy to previously used therapies, such as corticosteroids and surgeries. This report describes two cases of nasal tip infantile hemangioma, treated with oral propranolol. Both presented excellent therapeutic responses.


Subject(s)
Humans , Female , Infant , Propranolol/administration & dosage , Nose Neoplasms/drug therapy , Adrenergic beta-Antagonists/administration & dosage , Hemangioma/drug therapy , Nose Neoplasms/pathology , Administration, Oral , Treatment Outcome , Hemangioma/pathology
11.
Chinese Journal of Contemporary Pediatrics ; (12): 785-789, 2020.
Article in Chinese | WPRIM | ID: wpr-828666

ABSTRACT

OBJECTIVE@#To study the clinical effect of oral propranolol in the treatment of respiratory hemangioma in infants and young children.@*METHODS@#A retrospective analysis was performed from the chart review data of children with respiratory hemangioma treated by oral propranolol and diagnosed by bronchoscopy and laryngeal plain enhanced CT/MRI from November 2012 to December 2019.@*RESULTS@#A total of 20 children were enrolled. All children had improvement in the symptoms of laryngeal stridor and dyspnea after oral administration of propranolol for 1-2 days. The median treatment time was 10 months (range 6-12 months). The median follow-up time was 10 months (range 3-15 months). Of the 20 children, 19 (95%) achieved regression of tumor, and 1 (5%) experienced an increase in tumor size during reexamination at 6 months after drug withdrawal and had no recurrence after the treatment with an increased dose of propranolol for 6 months. Only 1 child (5%) had adverse reactions, and 1 child (5%) was still under treatment.@*CONCLUSIONS@#Oral propranolol can quickly relieve the symptoms such as dyspnea and achieve tumor regression, with few adverse events, and it is therefore an effective method for the treatment of respiratory hemangioma in infants and young children.


Subject(s)
Child , Child, Preschool , Humans , Infant , Administration, Oral , Adrenergic beta-Antagonists , Hemangioma , Neoplasm Recurrence, Local , Propranolol , Retrospective Studies , Treatment Outcome
13.
Rev. Paul. Pediatr. (Ed. Port., Online) ; 37(3): 392-395, July-Sept. 2019. graf
Article in English | LILACS | ID: biblio-1041337

ABSTRACT

ABSTRACT Objective: To present the outcomes of fixed doses of propranolol tablets for the treatment of hemangiomas. Case description: Two illustrative cases of hemangioma in infant patients younger than six months old are described. Treatments were started in 2010 and 2011 and were monitored until August 2017. Patients were treated with fixed doses, initially calculated based on the upper limit of 3 mg/kg/day and administrated in two daily doses rounded down to the nearest multiple of five milligrams. Dosage was not adjusted to patients' weight gain. The tablets were crushed and then diluted in a maximum amount of 3 mL of water. This procedure was necessary because propranolol was not available in oral solution in 2009, when dosages available in the Brazilian market were 10, 40 and 80 mg. Both patients presented significative improvement in the first 60 days and were in complete remission by the end of the treatment. Comments: It is possible to treat patients with Propranolol 10 mg tablets, even though the dosage is not as precise as when calculated according to patients' weight. The maintenance of a fixed dose, ignoring the patient's progressive weight gains, helps avoiding the rebound effect and decreases complications.


RESUMO Objetivo: Apresentar a experiência com a utilização de propranolol em doses fixas, em forma de comprimido, para o tratamento de hemangiomas. Descrição do caso: Dois casos ilustrativos de portadores de hemangiomas com menos de seis meses de idade são descritos. O início de tratamento ocorreu nos anos de 2010 e 2011 com seguimento até agosto de 2017. Os pacientes foram tratados com doses fixas iniciais calculadas com limite máximo de 3 mg/kg/dia, divididas em duas doses diárias, sempre com quantidades múltiplas de 5 mg. Os comprimidos de 10 mg ou a sua metade eram macerados e diluídos em 3 mL de água. As doses não foram mais alteradas. Esse uso foi decorrente da ausência da forma líquida de propranolol em 2009, quando começamos a utilizar esse tratamento, sendo então apenas disponíveis comprimidos de 10, 40 e 80 mg. Os pacientes obtiveram melhora acentuada nos primeiros 60 dias e remissão completa posteriormente. Comentários: É possível o uso de comprimidos de 10 mg, apesar de resultar numa dose não exata, como a calculada por kg/peso. A manutenção da mesma dose, mesmo com aumento progressivo de peso, pode evitar o efeito rebote e diminuir o índice de complicações.


Subject(s)
Humans , Female , Child , Propranolol/therapeutic use , Skin Neoplasms/drug therapy , Adrenergic beta-Antagonists/therapeutic use , Hemangioma/drug therapy , Propranolol/pharmacology , Skin Neoplasms/pathology , Weight Gain , Treatment Outcome , Adrenergic beta-Antagonists/pharmacology , Dose-Response Relationship, Drug , Hemangioma/pathology
14.
Journal of Southern Medical University ; (12): 328-336, 2019.
Article in Chinese | WPRIM | ID: wpr-772058

ABSTRACT

OBJECTIVE@#To study the effect of CYP2D610 (c.100 C>T) on plasma trough concentrations of metoprolol and its metabolite α-hydroxy metoprolol, blood pressure and heart rate in patients with coronary artery disease.@*METHODS@#The patients with coronary artery disease taking metoprolol tablets (=128) and those taking metoprolol sustained-release tablets (=126) were genotyped for CYP2D610 using Taqman real-time quantitative PCR. The trough concentrations of metoprolol and α-hydroxy metoprolol were determined with UPLC-MS/MS, and the dose-normalized concentrations (C/D) were compared among the patients with different CYP2D610 genotypes in both groups. Resting blood pressure and heart rate were recorded in all the patients when the concentration of metoprolol reached the steady state and were compared among the patients with different genotypes.@*RESULTS@#In patients taking metoprolol sustained-release tablets, the plasma trough concentration of α-hydroxy metoprolol was significantly associated with the systolic blood pressure (=0.0204). The CYP2D610 poor metabolizers showed a significant association with the C/D of metoprolol and α-hydroxy metoprolol ( < 0.01) in patients receiving metoprolol in both formulations, and in both groups, the C/D of metoprolol was significantly higher in the patients with a TT genotype than in those with a CC or CT genotype ( < 0.01); compared with those with the CT genotype, the patients with the TT genotype had a significantly lower C/D of α-hydroxy metoprolol ( < 0.01). In patients taking metoprolol sustained-release tablets, those with the CT (=0.0281) and TT (=0.0196) genotypes had lower diastolic blood pressure than patients with the CC genotypes, but the systolic blood pressure or heart rate did not differ significantly among them.@*CONCLUSIONS@#CYP2D610T allele mutation can reduce the metabolism of metoprolol, increase the C/D of metoprolol and decrease the C/D of α-metoprolol and diastolic blood pressure in patients with coronary artery disease, but CYP2D610 variation does not significantly affect systolic blood pressure or heart rate in the patients when the concentration of metoprolol reaches a steady state.


Subject(s)
Humans , Adrenergic beta-Antagonists , Chromatography, Liquid , Coronary Artery Disease , Cytochrome P-450 CYP2D6 , Genotype , Metoprolol , Tandem Mass Spectrometry
15.
Ciênc. Saúde Colet. (Impr.) ; 24(1): 67-75, ene. 2019. tab, graf
Article in Portuguese | LILACS | ID: biblio-974802

ABSTRACT

Resumo Queda recorrente representa alto risco de morbidade e mortalidade em idosos, principalmente institucionalizados, dado ao seu quadro de fragilidade e declínio funcional evidentes. O objetivo deste estudo é determinar a incidência e os fatores de risco relacionados a quedas recorrentes em idosos institucionalizados. Estudo longitudinal tipo coorte no período de um ano. Foram avaliados indivíduos com 60 anos ou mais residentes em 10 Instituições de Longa Permanência para Idosos, que deambulassem e possuíssem capacidade cognitiva preservada. Foi questionada a ocorrência de quedas nos últimos doze meses, considerando recorrentes a ocorrência de dois ou mais episódios neste período. Foram ainda coletadas variáveis referentes à instituição, condições sócio demográficas e de saúde do idoso através de questionários. Do total de 364 idosos, 130 foram incluídos. A incidência de quedas recorrentes foi de 26.9% (IC 95% = 22.4 - 31.5). A partir do Qui-quadrado e Regressão Logística, considerando o nível de significância de 5%, foi encontrada fadiga como fator de risco (p = 0.001; RR = 2.9) e uso de betabloqueadores como fator de proteção (p = 0.010; RR = 0.1). Conclui-se que queda recorrente é comum nas Instituições de Longa Permanência para Idosos e a fadiga representa fator de risco.


Abstract Recurrent falls constitute a high risk for morbidity and mortality among older people, especially institutionalized individuals, due to greater frailty and functional decline in this group. The aim of this study was to identify risk factors associated with recurrent falls among institutionalized older persons. A longitudinal cohort study was conducted over a one-year period with a study sample consisting of individuals aged 60 years and over living in 10 Nursing homes (NH) who were able to walk and had preserved cognitive ability. The older persons and carers were asked about the occurrence of falls over the last twelve months. The older persons were considered recurrent fallers if they had had two or more falls during this period. Institutional, sociodemographic and health data was also collected using questionnaires and the residents' medical records. One hundred and thirty individuals were included in the sample out of a total of 364 older people living in the NH. The incidence of recurrent falls was 26.9% (CI95% = 22.4 - 31.5). The results of the chi-square test and logistic regression adopting a significance level of 0.05 showed that fatigue was a risk factor for recurrent falls(p = 0.001; RR = 2.9) and that the use of beta blockers was a protective factor (p = 0.010; RR = 0.1). It was concluded that recurrent falls are common in NH and that fatigue constitutes an important risk factor.


Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Accidental Falls/statistics & numerical data , Fatigue/epidemiology , Frailty/epidemiology , Nursing Homes/statistics & numerical data , Recurrence , Logistic Models , Incidence , Surveys and Questionnaires , Risk Factors , Cohort Studies , Longitudinal Studies , Adrenergic beta-Antagonists/administration & dosage , Protective Factors , Middle Aged
16.
Arq. bras. oftalmol ; 81(6): 490-493, Nov.-Dec. 2018. tab
Article in English | LILACS | ID: biblio-973846

ABSTRACT

ABSTRACT Purpose: To evaluate whether any topical anti-glaucoma medications increase the risk of lacrimal drainage system obstruction or whether the presence of preservatives alone is sufficient to generate obstruction. Methods: This nested case-control study compared a group of patients with lacrimal duct obstruction who received topical anti-glaucoma medications to a control group of patients without obstruction. Results: The medical records of 255 patients with glaucoma who consulted the Oculoplastic Section with complaints of watery eyes were reviewed. Among these patients, 59 exhibited lacrimal drainage obstruction. Ninety-four percent of patients with lacrimal drainage obstruction used beta-blockers, and 41% used prostaglandin analogs. A logistic regression model was used to adjust for age, sex, and the use of other medications. No significant differences were observed regarding the topical anti-glaucoma medications used between groups. Conclusion: No single topical anti-glaucoma medication demonstrated a stronger association with the development of lacrimal duct obstruction.


RESUMO Objetivo: Avaliar se algum medicamento tópico anti-glaucoma aumenta o risco de obstrução do sistema de drenagem lacrimal ou se a presença de conservantes é su fi cien te para gerar obstrução. Métodos: Este estudo de caso-controle aninhado comparou um grupo de pacientes com obstrução do ducto lacrimal que receberam medicações tópicas anti-glaucoma contra um grupo controle de pacientes sem obstrução. Resultados: Foram revistos os prontuários de 255 pacientes com glaucoma que consultaram a Seção de Oculoplástica com queixas de olhos lacrimejantes. Dentre esses pacientes, 59 apresentavam obstrução da via lacrimal de drenagem. Noventa e quatro por cento dos pacientes com obstrução usaram betabloqueadores e 41% usaram análogos de prostaglandinas. Um modelo de regressão logística foi utilizado para ajustar a idade, sexo e o uso de outros medicamentos. Não foram observadas diferenças significativas em relação às medicações tópicas anti-glaucoma usadas entre os grupos. Conclusão: Nenhum medicamento anti-glaucoma tópico único demonstrou uma associação mais forte com o desenvolvimento de obstrução do ducto lacrimal.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Ophthalmic Solutions/therapeutic use , Glaucoma/drug therapy , Lacrimal Duct Obstruction/complications , Preservatives, Pharmaceutical/therapeutic use , Prostaglandins, Synthetic/therapeutic use , Carbonic Anhydrase Inhibitors/therapeutic use , Case-Control Studies , Glaucoma/complications , Retrospective Studies , Adrenergic beta-Antagonists/therapeutic use , Administration, Ophthalmic
17.
Rev. Soc. Bras. Clín. Méd ; 16(3): 176-179, jul.-set. 2018. tab., ilus.
Article in Portuguese | LILACS | ID: biblio-1047953

ABSTRACT

A miocardiopatia não compactada é uma doença congênita rara, que pode ocorrer isoladamente ou associada a outros defeitos, por falha no processo de compactação das fibras miocárdicas, resultando na persistência de trabeculações e recessos profundos. A associação entre a miocardiopatia não compactada e gestação é incomum na literatura, assim como a relação com macroglobulinemia de Waldenstrom, um tipo de linfoma não Hodgkin. Descrevemos aqui a rara associação destas três patologias. Trata-se de paciente do sexo feminino, sem antecedentes hematológicos, neoplasias ou cardiopatias, que procurou o serviço com queixa de astenia progressiva, dores no corpo, perda ponderal importante e anemia. Na investigação diagnóstica, a imunoeletroforese de proteína constatou pico monoclonal em IgM Kappa, com inventário medular por imunofenotipagem e biópsia de medula óssea com Kappa+, CD19+, CD20+, CD38 e CD79b, confirmando diagnóstico de neoplasia de linfócitos B maduros. Na terapêutica, optou-se pelo esquema de primeira linha com dexametasona, rituximabe e ciclofosfamida (DRC) − este último considerado agente alquilante cardiotóxico. Em triagem pré-quimioterápica, o eletrocardiograma mostrou alteração da repolarização ventricular anterosseptal. O ecocardiograma transtorácico evidenciou trabeculações excessivas no ápice do ventrículo esquerdo, sugerindo não compactação do miocárdio. A ressonância magnética confirmou o diagnóstico. Foi iniciada terapia com metoprolol e ácido acetilsalisílico. Todavia, após o último ciclo de terapia quimioterápica, paciente descobriu gravidez (G1P1A0). O período gestacional e o puerpério evoluíram sem manifestações clínicas de insuficiência cardíaca, em classe funcional I (New York Heart Association), mesmo com redução da fração de ejeção do ventrículo esquerdo ao ecocardiograma transtorácico. (AU)


Non-compaction cardiomyopathy is a rare congenital disease that can occur in isolation or associated with other defects, due to failure in compaction of myocardial fiber, resulting in persistence of myocardial trabeculations and deep recesses. The association between non-compaction cardiomyopathy and gestation, as well as the relationship with Waldenstrom's macrobulinemia, a type of Non-Hodgkin's Lymphoma (NHL), are not common in the literature. This study describes the rare association of these three pathologies. This is the case of a female patient with no history of hematological, neoplastic, or heart diseases, who sought the service with complaints of progressive weakness, body aches, important weight loss, and anemia. During the diagnostic investigation, protein immunoelectrophoresis showed a monoclonal peak in IgM Kappa monoclonal gammopathy, with a medullary inventory by immunophenotyping and bone marrow biopsy with Kappa+, CD19+, CD20+, CD38 and CD79b, confirming the diagnosis of mature B-cell lymphocyte neoplasm. The first line therapy chosen was dexamethasone, rituximab, and cyclophosphamide (CKD), with the latter being considered a cardiotoxic alkylating agent. At pre-chemotherapy screening, the electrocardiogram showed an alteration of the anteroseptal ventricular repolarization. Transthoracic echocardiography (ETT) showed excessive trabeculations at the apex of the left ventricle (LV), suggesting no compaction of the myocardium. The magnetic resonance imaging confirmed the diagnosis.Therapy with metoprolol and acetylsalicylic acid was started. However, after the last cycle of chemotherapy, the patient found she was pregnant (G1P1A0). The gestational and puerperium period progressed with no clinical manifestations of heart failure, in functional class I (New York Heart Association), albeit the reduction of the ejection fraction of the left ventricular shown in the transthoracic echocardiography. (AU)


Subject(s)
Humans , Female , Pregnancy , Adult , Pregnancy Complications, Cardiovascular/diagnostic imaging , Pregnancy Complications, Neoplastic/diagnosis , Waldenstrom Macroglobulinemia/diagnosis , Cardiomyopathies/diagnostic imaging , Thrombocytopenia/drug therapy , Biopsy, Needle , Dexamethasone/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Echocardiography , Magnetic Resonance Spectroscopy , Waldenstrom Macroglobulinemia/drug therapy , Adrenergic beta-Antagonists/therapeutic use , Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Agents, Alkylating/therapeutic use , Cyclophosphamide/therapeutic use , Electrocardiography , Rituximab/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use
18.
Rev. Assoc. Med. Bras. (1992) ; 64(8): 745-754, Aug. 2018. tab, graf
Article in English | LILACS | ID: biblio-976841

ABSTRACT

SUMMARY OBJECTIVES This study aimed at assessing the role of beta-blockers on preventing anthracycline-induced cardiotoxicity in adults. METHODS A systematic review was performed on electronic databases, including relevant studies that analysed beta-blockers as cardioprotective agents before the use of anthracyclines by adult oncologic patients. RESULTS After application of eligibility and selection criteria, eight articles were considered as high quality, complying with the proposed theme; all eight clinical trials, four of them placebo-controlled, with a total number of 655 patients included. From this sample, 281 (42.9%) used beta-blocker as intervention, and carvedilol was the most frequent (167 patients - 25.5%). Six studies were considered positive regarding the cardioprotection role played by beta-blockers, although only four demonstrated significant difference on left ventricle ejection fraction after chemotherapy on groups that used beta-blockers compared to control groups. Carvedilol and nebivolol, but not metoprolol, had positive results regarding cardioprotection. Other beta-blockers were not analysed in the selected studies. CONCLUSIONS Despite the potential cardioprotective effect of beta-blockers, as demonstrated in small and unicentric clinical trials, its routine use on prevention of anthracycline-associated cardiotoxicity demands greater scientific evidence.


RESUMO OBJETIVO Este estudo teve como objetivo analisar o papel dos betabloqueadores na prevenção da cardiotoxicidade induzida pelas antraciclinas em adultos. MÉTODOS Foi realizada uma revisão sistemática em bases de dados eletrônicos, incluindo os estudos relevantes que analisaram fármacos betabloqueadores como agentes cardioprotetores antes do início do uso de antraciclinas por pacientes oncológicos adultos. RESULTADOS Após aplicação dos critérios de elegibilidade e seleção, foram obtidos oito artigos considerados de boa qualidade, que se adequavam à temática proposta, sendo todos ensaios clínicos, quatro placebo-controlados, totalizando 655 pacientes incluídos. Destes, 281 (42,9%) fizeram uso de algum betabloqueador como intervenção, sendo o carvedilol o mais utilizado (167 pacientes - 25,5%). Seis estudos foram considerados positivos quanto à cardioproteção exercida pelos betabloqueadores, porém apenas quatro demonstraram diferença na fração de ejeção do ventrículo esquerdo após a quimioterapia nos grupos que usaram betabloqueadores em relação aos grupos controle. O carvedilol e o nebivolol, mas não o metoprolol, tiveram resultados positivos quanto à cardioproteção. Outros betabloqueadores não foram avaliados nos estudos incluídos. CONCLUSÕES Apesar de haver um potencial efeito cardioprotetor dos betabloqueadores, conforme demonstrado em ensaios clínicos pequenos e unicêntricos, sua utilização rotineira na prevenção da cardiotoxicidade associada às antraciclinas requer maiores comprovações científicas.


Subject(s)
Humans , Adult , Cardiotonic Agents/pharmacology , Adrenergic beta-Antagonists/pharmacology , Anthracyclines/adverse effects , Heart Diseases/chemically induced , Heart Diseases/prevention & control , Stroke Volume , Cardiotonic Agents/therapeutic use , Reproducibility of Results , Adrenergic beta-Antagonists/therapeutic use , Cardiotoxicity/prevention & control , Carvedilol/therapeutic use , Carvedilol/pharmacology
19.
Article in Portuguese | LILACS | ID: biblio-913926

ABSTRACT

A fibrilação atrial é a arritmia mais frequentemente encontrada após cirurgia cardíaca. Embora geralmente autolimitada, representa um importante preditor de aumento de morbimortalidade e de custos aos sistemas de saúde. Numerosos estudos tentaram determinar os mecanismos associados à fibrilação atrial no pós-operatório com resultados variados. Uma fisiopatologia multifatorial é sugerida, sendo o processo inflamatório e a ativação simpática adrenérgica do período pós-operatório reconhecidos como importantes fatores de contribuição. O tratamento é dificultado pela escassez de dados relativos aos resultados de diferentes intervenções terapêuticas nessa população. Este artigo analisa a literatura cujo foco sejam as intervenções para prevenir a fibrilação atrial no pós-operatório


Atrial fibrillation is the most commonly found arrhythmia after cardiac surgery. Although usually self-limiting, it represents an important predictor of increased patient morbidity, mortality, and health care costs. Numerous studies have attempted to determine the underlying mechanisms of postoperative atrial fibrillation with different results. A multifactorial pathophysiology is suggested, with inflammation and postoperative adrenergic activation recognized as important contributing factors. The management is complicated by a lack of data on the outcomes of different therapeutic interventions in this population. This article reviews the literature focusing on interventions to prevent postoperative atrial fibrillation


Subject(s)
Humans , Male , Female , Atrial Fibrillation/physiopathology , Disease Prevention , Postoperative Period , Thoracic Surgery/methods , Adrenergic beta-Antagonists/therapeutic use , Anti-Arrhythmia Agents/therapeutic use , Arrhythmias, Cardiac , Indicators of Morbidity and Mortality , Oxidative Stress , Risk Factors , Sotalol/therapeutic use
20.
Acta cir. bras ; 33(2): 125-133, Feb. 2018. tab, graf
Article in English | LILACS | ID: biblio-886259

ABSTRACT

Abstract Purpose: To investigate the biochemical, histopathologic, and spermatogenetic changes in the detorsionated testicle after experimental torsion and to study the antioxidant effects of pheniramine maleate and nebivolol. Methods: Twenty-four Sprague-Dawley male rats were divided into 4 groups: Group 1: Sham; Group 2: Torsion/Detorsion (T/D); Group 3: T/D + Pheniramine maleate (PM); Group 4: T/D + Nebivolol (NB) group. Paroxanase (PON), total antioxidant status (TAS), total oxidant status (TOS), and oxidative stres index (OSI) were measured, and spermatogenetic and histopathologic evaluation was performed in tissue and blood samples. Results: The evaluation of tissue TAS indicated no statistically significant difference in Group 3 compared to Group 2. A statistically significant increase was detected in Group 4 compared to Group 2. Serum PON levels revealed a statistically significant increase in Groups 3 and 4 compared to Groups 1 and 2. The Johnsen testicular biopsy score decreased in Groups 3 and 4, but the decrease was not statistically significant. Conclusions: Pheniramine maleate and nebivolol have antioxidant effects against ischemia-reperfusion damage. They also support tissue recovery, which is more significantly observed by nebivolol.


Subject(s)
Animals , Male , Rats , Pheniramine/pharmacology , Spermatic Cord Torsion/drug therapy , Testis/drug effects , Oxidative Stress/drug effects , Nebivolol/pharmacology , Antioxidants/pharmacology , Spermatic Cord Torsion/pathology , Spermatogenesis/drug effects , Testis/blood supply , Testis/pathology , Time Factors , Reperfusion Injury/drug therapy , Rats, Sprague-Dawley , Adrenergic beta-Antagonists/pharmacology , Aryldialkylphosphatase/blood , Histamine H1 Antagonists/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL